Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
13.74
-0.66 (-4.58%)
At close: Jun 27, 2025, 4:00 PM
13.95
+0.21 (1.53%)
After-hours: Jun 27, 2025, 7:33 PM EDT
Arcutis Biotherapeutics Revenue
Arcutis Biotherapeutics had revenue of $65.85M in the quarter ending March 31, 2025, with 32.84% growth. This brings the company's revenue in the last twelve months to $212.82M, up 100.03% year-over-year. In the year 2024, Arcutis Biotherapeutics had annual revenue of $196.54M with 229.74% growth.
Revenue (ttm)
$212.82M
Revenue Growth
+100.03%
P/S Ratio
8.05
Revenue / Employee
$622,278
Employees
342
Market Cap
1.64B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARQT News
- 1 day ago - Arcutis' ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis - GlobeNewsWire
- 2 days ago - Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
- 14 days ago - Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
- 17 days ago - Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis - GlobeNewsWire
- 21 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 21 days ago - Arcutis to Present New Long-Term Results of ZORYVE® (roflumilast) Cream at the 2025 Revolutionizing Atopic Dermatitis Conference - GlobeNewsWire
- 22 days ago - Arcutis Biotherapeutics: Navigating Commercialization With Promising Upside - Seeking Alpha
- 4 weeks ago - Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire